The data derived from this study and information on the structure of the female population of England and Wales derived from the Registrar General's report make it possible to estimate the mortality from myocardial infarction in women who use oral contraceptives and in those who do not. In the 30-39-year age group the yearly death rate in women not using these preparations is estimated to be 1-9 per 100 000 compared with 5-4 per 100 000 in women who are using them. In the 40-44-year age group the yearly death rates are 11-7 and 54-7 per 100 000 respectively.* It seems, then, that the risk of death from myocardial infarction was increased about [2] [3] [4] [5] [6] [7] [8] times in current users of oral contraceptives aged 30-39 years and about 417 times in women aged 40-44 years.
In absolute terms the attributable mortality was considerably lower in women aged 30-39 years than in those aged 40-44 years, there being an excess of 3-5 deaths per 100 000 users yearly in the former group and 43 per 100 000 users yearly in the latter group. These estimates of risk are similar to the increased risk of non-fatal infarction estimated by Mann et al.1" but still need to be interpreted with caution, as a number of assumptions have necessarily had to be made in their calculation and the margin of error is likely to be fairly wide. We do, nevertheless, consider them to be helpful in providing a crude estimate of risk of death from myocardial infarction in women currently using oral contraceptives. *These data are too few to justify making estimates for women aged [45] [46] [47] [48] [49] years, in whom the yearly mortality rate in 1973 (table IV) . With each Bishop score the latent interval varied. Nevertheless, cumulative frequency tables showed that in all primigravidae labour was established within four hours when the score was 9 or more at the start, within six hours when it was 7-8 at the start, and within eight hours when it was 6 or less at the start. In multiparous women labour was established within four hours when the score was 9 or more at the beginning of the regimen. When the score was either 1-2 or 5-6 at the start labour was always established within six hours. With scores of 7-8 and 3-4 labour was not established in all multiparae until after eight hours. The mean total dose of oxytocin infused during the latent interval varied from 1-24 ± 2-46 to 7-64 : 5-46 U in primigravid patients and 1-24 ± 1 91 to 4-28 : 3 99 U in multiparous women.
MAINTENANCE OF LABOUR
Labour was maintained satisfactorily in only three out of 22 women (13-6%) in whom the infusion of oxytocin was reduced to 7 mU/min when dilatation of the cervix was less than 2 cm. In contrast, when dilatation had reached 5 cm or more when the infusion was reduced progress continued satisfactorily in all women (table V) . There was no significant difference between the primigravid and multiparous women (tables VI and VII). hypertonus, intrapartum fetal anoxia, rapid labour, and deep transverse arrest of the fetal head. We therefore made a limited comparison between the methods of delivery used in this study and for 945 women of similar gestation and in whom there was no clinical suspicion of cephalopelvic disproportion and who were delivered in the same hospital during 1973. In both groups all labours were induced by an identical technique, except that in 1973 once labour became established the oxytocin infusion rate was not reduced to 7 mU/min but was maintained at a greater though constant rate. The incidence of normal delivery was similar in both groups. In the present study no ventouse extractions were necessary and no caesarean sections were performed. In 1973 3% of the patients were delivered by these methods. Fetal distress was never the indication for operative intervention in patients receiving only 7mU oxytocin/min to maintain labour. In 1973 fetal distress, confirmed by blood pH estimation, was the chief indication for operative delivery in 32% of the group.
Whereas variable amounts of oxytocin are required to induce labour to the stage of 5 cm dilatation of the cervix within a reasonably short time, our results show that no more than 7 mU/min is necessary to maintain labour satisfactorily thereafter. Larger doses at this time may be attended by obstetric problems. We therefore recommend the adoption of a maintenance regimen whenever established labour has been induced. failure,2 would suggest either a natural loss of antipseudomonal activity in vivo or else an extrarenal pathway of excretion.
This study was designed to investigate the human pharmacology and toxicology of carfeciJlin and assess the drug's value in treating urinary infections in hospital inpatients, particularly those in whom Pseudomonas aeruginosa was the causative pathogen.
Patients and Methods

VOLUNTEER STUDY
Carfecillin 500 mg or 1000 mg by mouth (equivalent to 397 mg and 794 mg of carbenicillin free acid respectively) was given to 10 healthy volunteers two hours after a light breakfast of beverage and toast. Carbenicillin levels were assayed in serial blood samples over eight hours during which about 125 ml of water was allowed every half hour. Urinary recovery of carbenicillin was measured over three consecutive four-hour periods from the beginning of the study. All serum and urine carbenicillin concentrations were assayed by a wellplate microbiological diffusion assay method using Ps. aeruginosa (NCTC 10490) as test organism. Serum samples were also investigated for the presence of free phenol by a standard gas-liquid chromatographic method, using an ether/acid extraction process which could detect less than 0-5 mg/l free phenol.
Four of the volunteers subsequently took either 500 mg or 1000 mg of carfecillin every eight hours over four days while receiving their normal diet. Serial carbenicillin levels were determined as before on days two and four, and all urine was collected for assay throughout the period.
Four patients with renal failure (creatinine clearance < 2-2 ml/min) who had given informed consent took either two or three doses of carfecillin 1000 mg by mouth at four-hourly intervals. Serum carbenicillin levels were assayed throughout the period. Two of the patients were anuric, so urinary carbenicillin levels were measured only in two.
THERAPEUTIC TRIAL
A therapeutic trial of carfecillin in 35 inpatients with urinary infections was then undertaken. Doses of 1000 mg were given by mouth every eight hours for seven days. Serum levels of carbenicillin were measured in 18 patients one and two hours after the initial dose, and the urinary recovery of carbenicillin was determined in all patients
